Serum calprotectin is useful to confirm inflammatory bowel disease activity but not to predict relapse

Autor: Pauline Veyrard, Xavier Roblin, Céline Pansart, Ren Mao, Stéphane Nancey, Martin Killian, Louis Waeckel, Anne-Emmanuelle Berger, Nicolas Williet, Laetitia Bastide, Mathilde Barrau, Quentin Tournier, Stéphane Paul

Publikováno v: Clinical Immunology Communications, Vol 2, Iss , Pp 33-38 (2022)

Aim: Serum calprotectin (SC), a novel biomarker of inflammatory bowel diseases (IBD), has been recently investigated with conflicting results. The purpose of this study was to assess the ability of SC to predict relapse in IBD patients treated by bio

Externí odkaz: https://doaj.org/article/2caf60cdd62543b4a4c3263434463a11

Efficacy of induction therapy with calcineurin inhibitors in combination with ustekinumab for acute severe ulcerative colitis

Autor: Pauline Veyrard, Gauthier Pellet, David Laharie, Maria Nachury, Pascal Juillerat, Xavier Roblin

Publikováno v: Veyrard, P; Pellet, G; Laharie, D; Nachury, M; Juillerat, P; Roblin, X (2023). Efficacy of induction therapy with calcineurin inhibitors in combination with ustekinumab for acute severe ulcerative colitis. Clinical gastroenterology and hepatology, 21(5), 1354-1355.e2. Elsevier 10.1016/j.cgh.2022.03.008

Ulcerative colitis is a chronic inflammatory bowel disease. Approximately 20% of patients experience an acute severe attack during their life. In acute severe ulcerative colitis (ASUC), first-line therapy is intravenous (IV) steroids. In the absence

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7851a4a3743fcd64dd18b05d2a21d31
https://boris.unibe.ch/167856/1/1-s2.0-S1542356522002828-main.pdf

Swapping Versus Dose Optimization in Patients Losing Response to Adalimumab With Adequate Drug Levels

Autor: Jean-Marc Phelip, Bernard Flourié, Pauline Veyrard, Gilles Boschetti, Martin Killian, Anne-Emmanuelle Berger, Xavier Roblin, Stéphane Paul, Nicolas Williet, Capucine Genin, Louis Waeckel, Stéphane Nancey

Publikováno v: Inflammatory Bowel Diseases. 28:720-727

Background In cases of loss of response due to mechanistic failure under antitumor necrosis factor agents, it is recommended to switch to another class of biologics. Two different strategies were compared in patients with inflammatory bowel disease (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dd0e60b1d03e76274b9dfefabcf7eba
https://doi.org/10.1093/ibd/izab158

Corticosteroids and Mesalamine Versus Corticosteroids for Acute Severe Ulcerative Colitis: A Randomized Controlled Trial

Autor: Shomron Ben-Horin, Ofir Har-Noy, Konstantinos H. Katsanos, Xavier Roblin, Minhu Chen, Xiang Gao, Doron Schwartz, Jae Hee Cheon, Monica Cesarini, Daniela Bojic, Marijana Protic, Angeliki Theodoropoulou, Heba Abu-Kaf, Tal Engel, Jian Tang, Pauline Veyrard, Xiaoqing Lin, Ren Mao, Dimitrios Christodoulou, Konstantinos Karmiris, Tamara Knezevic-Ivanovski

Publikováno v: Clinical Gastroenterology and Hepatology. 20:2868-2875.e1

Corticosteroids are the mainstay of treatment for hospitalized patients with acute severe ulcerative colitis (ASUC). However, whether the addition/continuation of mesalamine with corticosteroids during hospitalization is superior to corticosteroids a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3eb29574af6d5f45c1184ed2c134b955
https://doi.org/10.1016/j.cgh.2022.02.055

Effectiveness and safety of ustekinumab intensification at 90 Mg every four weeks In Crohn's disease: a multicenter study

Autor: Mathurin, Fumery, Laurent, Peyrin-Biroulet, Stephane, Nancey, Romain, Altwegg, Cyrielle, Gilletta, Pauline, Veyrard, Guillaume, Bouguen, Stephanie, Viennot, Florian, Poullenot, Jerome, Filippi, Anthony, Buisson, Anne, Bozon, Franck, Brazier, Lieven, Pouillon, Bernard, Flourie, Lucile, Boivineau, Laurent, Siproudhis, David, Laharie, Xavier, Roblin, Momar, Diouf, Xavier, Treton

Publikováno v: Journal of Crohn's and Colitis
Journal of Crohn's and Colitis, 2021, 15 (2), pp.222-227. ⟨10.1093/ecco-jcc/jjaa177⟩
Journal of Crohn's and Colitis, Elsevier-Oxford University Press, 2021, 15 (2), pp.222-227. ⟨10.1093/ecco-jcc/jjaa177⟩

International audience; Introduction: The approved maintenance regimens for ustekinumab in Crohn's disease (CD) are 90 mg every 8 or 12 weeks. Some patients will partially respond to ustekinumab or will experience a secondary loss of response. It rem

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::8b0b2a0fa0dc81a79e014e5c3f29d52a
https://doi.org/10.1093/ecco-jcc/jjaa177